• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Sonus completes phase-one trials

Article

Ultrasound contrast agent developerSonus Pharmaceuticals announced this month that its EchoGen agenthas completed phase-one clinical trials. Sonus, of Bothell, WA,made the announcement at the Alex. Brown & Sons Medical Conferencein Baltimore.

Ultrasound contrast agent developerSonus Pharmaceuticals announced this month that its EchoGen agenthas completed phase-one clinical trials. Sonus, of Bothell, WA,made the announcement at the Alex. Brown & Sons Medical Conferencein Baltimore.

EchoGen is the first agent in the Sonus pipeline. It is basedon an emulsion that turns into echogenic microbubbles when injected(SCAN 1/19/94).

The phase-one trial involved administration of EchoGen to 25healthy male subjects and obtaining blood samples to measure drugcontent and to detect potential safety parameters over a 72-hourperiod.

EchoGen appeared safe under the conditions of the study andthe drug was cleared from the body quickly after images were obtained,according to Sonus president and CEO Dr. Steven C. Quay.

In addition, EchoGen provided diagnostically useful informationabout heart, kidney and liver function and the vascular systemin 88% of the subjects in the study. Sonus will use the resultsof the study to develop phase-two clinical trials for EchoGenin cardiology and radiology, as well as an exercise-stress echocardiologystudy for myocardial perfusion.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.